Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Celgene Corporation : Celgene's Profits Fall, But Focus Remains on Pipeline

share with twitter share with LinkedIn share with facebook
share via e-mail
01/24/2013 | 07:47pm CEST

--Celgene's Q4 net falls, while revenues rise

--FDA approval decision for multiple myeloma drug Pomalyst expected in February

--Celgene shares down 2.4% to $97.64 so far this week as investors take profits

(Updates throughout adding details and analyst comment.)

   By Joseph Walker and Melodie Warner 

Celgene Corp.'s (CELG) fourth-quarter earnings fell 36% as restructuring costs and other special items hurt the drug maker's margins and masked its increased revenue.

The results had been expected since the Summit, N.J., company pre-announced full-year results for 2012 and 2013 guidance at an investor meeting earlier this month.

Celgene's revenues jumped 13% to $1.45 billion in the quarter, largely on the strength of its core blood-cancer drug franchise, which includes the blockbuster Revlimid treatment.

However, investor attention has been focused on the company's late-stage product pipeline, which includes what Celgene says are three "potential blockbusters" that would expand the company's portfolio into new disease areas.

The first of those drugs likely to reach the market is Pomalyst, a treatment for the patients with relapsed multiple myeloma, a bone marrow cancer. The U.S. Food and Drug Administration is scheduled to make an approval decision by Feb. 10. Celgene said it would launch the drug shortly after approval.

"Our commercial and medical affairs teams are ready to launch and support the thousands of patients who have exhausted all existing myeloma therapies," Celgene Executive Vice President Mark Alles said. "Successfully launching Pomalyst is a major corporate objective and we are ready."

Celgene shares fell 0.6% to $97.64, and are down 2.4% so far this week as investors take profits. Even with the recent slide, the stock has soared 24% in 2013, as investors have placed a high premium on the company's pipeline.

Celgene also plans to seek FDA approval for apremilast, a treatment for the skin disease Psoriasis, and its cancer drug Abraxane for patients with pancreatic cancer this year. Both drugs are projected to be generate billions of dollars annually for Celgene.

The new drugs are part of Celgene's strategy to expand beyond its core hematology franchise and build out new product lines in cancer to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $263.1 million, or 61 cents a share, down from $410.2 million, or 91 cents, a year earlier. Excluding items such as stock-based compensation, acquisition and restructuring costs, adjusted per-share earnings rose to $1.32 from $1.05 a year ago.

Analysts polled by Thomson Reuters had forecast earnings of $1.31 a share on revenue of $1.46 billion.

Revlimid sales jumped 17% to $1 billion, while Vidaza sales climbed 14% to $216 million.

Gross margin fell to 22.2% from 31.5% as costs rose because of preparations for the launches of Abraxane for non-small-cell lung cancer and Pomalyst. Abraxane received FDA approval for that indication in October.

Write to Joseph Walker at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
06/22CELGENE CORPORATION : Announces Appointment of Jonathan Biller as Executive Vice..
06/22Celgenes CAR T Cell Therapy Could Be Long-Term Growth Driver
06/21Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks
06/20ACCELERON PHARMA : Announces Updated Results from Ongoing Phase 2 Trials of Lusp..
06/19CELGENE CORP /DE/ : Other Events, Financial Statements and Exhibits (form 8-K)
06/19CELGENE CORPORATION : Announces Appointment of Jonathan Biller as Executive Vice..
06/19NASDAQ 100 MOVERS : Jd, regn
06/19ELOXX PHARMACEUTICALS : Appoints Global Pharmaceutical Leader, Neil Belloff, Exe..
06/19Payers, drugmakers face off over CAR T Medicare coverage
06/15CELGENE : CREATES could face uphill battle in Senate
More news
News from SeekingAlpha
12:24pGENOMIC MEDICINE : Is The Platform The FDA Product? 
08:30aGeron's EHA Data Begin To Paint A Clearer Picture. Is It For Good Or Ill? 
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/21Forty Seven Readies $100 Million U.S. IPO 
06/183 THINGS IN BIOTECH, JUNE 17 : Ruxolitinib Climbs Higher 
Financials ($)
Sales 2018 14 908 M
EBIT 2018 8 447 M
Net income 2018 4 829 M
Debt 2018 6 033 M
Yield 2018 -
P/E ratio 2018 12,37
P/E ratio 2019 9,78
EV / Sales 2018 4,24x
EV / Sales 2019 3,21x
Capitalization 57 116 M
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 113 $
Spread / Average Target 43%
EPS Revisions
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-12.08%329 475
PFIZER0.80%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-10.81%191 785